Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer.

World J Gastrointest Oncol · 2024 · PMC11236229 · PMID 38994132

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

failed to reach statistical significanceP > 0.05actually significant

Similarly, these numerical differences in the 6-month PFS, 1-year OS, and 3-year OS also failed to reach statistical significance ( P > 0.05).

also in 805 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.